NTSR2 and prostate carcinoma: The NTR1 overexpression has been demonstrated in a tumor progression, e.g., in pancreas and colon adenoma, but also in breast, lung, or prostate cancer, while the expression of NTR2 has been reported in prostate cancer, lymphatic leukemia, and glioma [175].